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Abstract The lymphatic vascular system has an important
role in the maintenance of tissue fluid pressure homeostasis,
in the mediation of the afferent immune response via
recruitment of antigen-presenting cells toward draining
lymph nodes, and in the intestinal absorption of dietary
lipids. Substantial progress in our understanding of the
development and the molecular mechanisms controlling the
lymphatic system has been made during the last few years,
based on a recent wave of discoveries of lymphatic
endothelial cell-specific markers and growth factors. This
has also led to new insights into the role of lymphatic
endothelium in a number of diseases, including primary and
secondary lymphedemas. The emerging role of lymphatic
endothelium in the context of inflammation indicates that
therapeutics targeting the lymphatic vasculature might
represent a new strategy for anti-inflammatory therapies.
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Introduction
To cope with the complex needs of transporting fluids,
gases, nutrients, signaling molecules, and cells through
tissues, vertebrate organisms have developed two comple-
mentary vascular networks, the blood and the lymphatic
vasculatures. The physiology of the blood vascular system
and the role of angiogenesis (the growth of new blood
vessels from pre-existing ones) in disease have been
thoroughly studied over the last few decades (Carmeliet
2003). In contrast, substantial progress in our understanding
of the development and molecular mechanisms controlling
the lymphatic system, first identified almost four centuries
ago (Asellius 1627), has only been made during the last few
years, based on a recent wave of discoveries of lymphatic
endothelial cell (LEC) markers and growth factors. Al-
though the endothelial cells of blood vessels (BECs) and of
lymphatic vessels have many features in common, such as
their apical-basal polarity and the expression of certain pan-
endothelial markers, the unique functional roles of these
two vascular networks require extensive specialization.
Physiological functions of the lymphatic vascular system
Tissue fluid homeostasis
The primary role of the lymphatic vascular system is the
maintenance of tissue fluid homeostasis by draining excess
interstitial fluid (leaking from blood capillaries) and
returning it into the blood flow. The lymphatic vascular
network is composed of initial lymphatic capillaries and of
collecting lymphatic vessels. The initial lymphatic vessels
lack a basement membrane and are thin-walled with wide
lumina lined by a single layer of overlapping LECs that are
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anchored to the extracellular matrix by fibrillin-containing
anchoring filaments (Gerli et al. 2000). Under conditions of
high interstitial pressure, lymphatic capillaries are pulled
open by these anchoring filaments, facilitating the uptake of
fluid, macromolecules, and cells. The importance of
anchoring filaments and the extracellular matrix for
lymphatic drainage has recently been demonstrated in
extracellular matrix glycoprotein Emilin1-deficient mice
(Danussi et al. 2008). These mice display pronounced
lymphatic drainage impairment and increased lymphatic
leakage.
Lymph flow is unidirectional from the lymphatic
capillaries to larger collecting lymphatics and finally into
the thoracic duct, which empties into the inferior vena cava
(Cueni and Detmar 2006). The forces that move the lymph
through the vessels include smooth muscle contraction
along the collecting vessels, respiratory movements, and
skeletal muscle action (Bridenbaugh et al. 2003). Collecting
lymphatic vessels differ from initial lymphatic capillaries in
several aspects, in addition to their larger diameter. They
are covered by smooth muscle cells and contain intra-
luminal valves that prevent the backflow of lymph. The
exact mechanisms of fluid uptake by initial lymphatic
vessels have remained unclear. However, recent studies
indicate that overlapping flaps of oak-leaf-shaped LECs of
the initial lymphatics lack intercellular junctions at the tip
but are anchored on their sides by discontinuous button-like
junctions. These differ from the continuous zipper-like
junctions seen in the collecting lymphatics (Baluk et al.
2007).
Immune cell trafficking and immune surveillance
The lymphatic system also plays a major role in immune
reactions. Immune cells such as antigen-presenting dendrit-
ic cells, memory T lymphocytes, and macrophages and
soluble antigens use the lymphatic network to drain from
peripheral tissues to regional lymph nodes where the
immune responses are initiated (Cavanagh and Von
Andrian 2002). There is increasing evidence for an active
role of lymphatic endothelium in mediating the entry of
antigen-presenting cells and lymphocytes into lymphatic
vessels (Johnson et al. 2006; Randolph et al. 2005). Indeed,
the interaction of immune cells with lymphatics represents
an important step in the regulation of the immune response
(Ledgerwood et al. 2008). The molecular mechanisms
involved will be discussed in more detail below in the
context of lymphatic vessel involvement in inflammation.
Dietary fat absorption by intestinal lymphatics
Within the small intestine, specialized lymphatic vessels in
the villi, called lacteals, absorb dietary lipids and the fat-
soluble vitamins A, D, E, and K. Mucosal enterocytes
assemble chylomicrons, viz., lipoprotein complexes of
100–2000 nm in diameter, that are exocytosed into the
lamina propria where they come into contact with the
lacteals (Blomhoff et al. 1990). Chylomicrons constitute up
to 15% of the lymph volume after ingestion of a fat-
containing meal. Little is known concerning the modifica-
tions of chylomicrons permitting their uptake by lacteal
vessels (Van Dyck et al. 2007) or regarding the mechanisms
of lipid uptake into lymphatics. However, recent studies
have indicated the presence of a link between fat
metabolism and lymphatic function in the intestine, based
on studies in mice with a deficiency of fasting-induced
adipose factor (Fiaf, also known as angiopoietin-like
protein-4; Backhed et al. 2007) or of the lymphatic-specific
transcription factor Prox1. Prox1 heterozygous mice die
within the first 2–3 days after birth on all except one
genetic background (Wigle and Oliver 1999). The surviving
mice show adult onset obesity with fat deposits in the tissue
surrounding the leaky lymphatics (Harvey et al. 2005).
Prox1 heterozygous mice also have high levels of circulat-
ing insulin and leptin. Additional evidence for a relation-
ship between lymphatic vessels and adipose tissue come
from the observation of ectopic adipose tissue growth in
edematous regions of individuals with chronic lymphedema
(Brorson et al. 2006), and lymph fluid has been reported
directly to promote adipocyte differentiation in vitro
(Harvey et al. 2005). Studies into the mechanisms of lipid
absorption by intestinal lymphatics are needed and might
lead to a better understanding of malabsorption syndromes/
vitamin deficiencies and of the mechanisms of intestinal
lymphatic drug transport (Nordskog et al. 2001).
Development of the lymphatic vasculature
At the beginning of the last century, two opposing models
for the embryonic development of the lymphatic system
were proposed. Based upon results obtained by ink
injection experiments, Florence Sabin proposed that isolat-
ed primitive lymph sacs originated from endothelial cells
that bud from the cardinal vein during early development
(Sabin 1902). The two jugular lymph sacs were thought to
develop at the junction of the subclavian and anterior
cardinal veins. According to this model, the peripheral
lymphatic system originates from the primary lymph sacs
and spreads by endothelial sprouting into the surrounding
tissues and organs, where local capillaries are formed (Gray
1985; Sabin 1902). An alternative model proposed that
lymphatic vessels developed independently from mesen-
chymal precursor cells (but not from embryonic veins), and
that connections with veins were only established later on
during development (Huntington and McClure 1910).
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At present, most experimental evidence supports Sabin’s
model of embryonic lymphatic development. A number of
molecular genetics studies have shown that LECs do indeed
sprout from the veins in the jugular area, and studies in
Prox1 deficient mice have provided insight into the
molecular players involved in this process (Wigle et al.
2002; Wigle and Oliver 1999). Recently, a Cre/loxP-based
lineage-tracing study of mice expressing Cre recombinase
under the control of Tie2, Runx1, or Prox1 promoter
elements has provided strong evidence that the mammalian
lymphatic system has a venous origin only (Srinivasan et al.
2007). However, circulating bone-marrow-derived cells
have been found, at a small percentage of lymphatic vessels
affected, to participate in experimental corneal lymphangio-
genesis and in chronic renal transplant rejection (Kerjaschki
et al. 2006; Religa et al. 2005). The relevance of these ob-
servations for normal lymphatic development is unknown.
Molecular control of lymphatic vascular development
The homeodomain transcription factor Prox1 is the earliest
protein known to be expressed in a polarized fashion in the
cardinal vein (Wigle and Oliver 1999). A number of studies
have revealed that Prox1 is a master gene controlling
lymphatic-specific differentiation (Hong et al. 2002; Petrova
et al. 2002; Wigle et al. 2002). In mice, Prox1-positive cells
appear around embryonic day 9.5 (E9.5) in the cardinal
vein and then bud off and migrate to form the first lymph
sacs (Fig. 1). Prox1 null embryos die at approximately
E14.5 and completely lack a lymphatic vasculature without
defects of the blood vasculature (Wigle and Oliver 1999).
Prox1 is at present considered to be the most specific
lineage marker of the lymphatic endothelium (Wigle et al.
2002). Little is known about the signals upstream of Prox1
that lead to lymphatic commitment of blood vascular
endothelium. In contrast, a number of Prox1 target genes
have been identified. Overexpression of Prox1 in cultured
vascular endothelial cells leads to a lymphatic reprogram-
ming of these cells with upregulation of LEC markers and
suppression of certain BEC markers (Hong et al. 2002;
Petrova et al. 2002). Prox1 also increases endothelial cell
motility and migration (Mishima et al. 2007; Dadras et al.
2008 (in press). LYVE-1, a homolog of the hyaluronan
receptor CD44 (Banerji et al. 1999), is the first marker of
lymphatic competence and is expressed in the cardinal vein
at E8.5 (Oliver 2004). In adults, LYVE-1 is expressed not
Fig. 1 Current model of the stepwise embryonic development of the
mammalian lymphatic system. During early vascular development,
endothelial cells of the embryonic cardinal vein express the two
lymphatic markers LYVE1 and vascular endothelial growth factor
receptor-3 (LYVE1+ and VEGFR-3+; stage of lymphatic competence).
Stimulation by an as yet unidentified mesenchymal signal induces
expression of the transcription factor Prox1 in a subset of endothelial
cells at the lateral side of the cardinal vein (Prox1+; stage of
lymphatic commitment). These cells bud off from the vein and
migrate into the surrounding tissue to form primitive lymph sacs.
During this process, they adopt the expression of additional lymphatic
lineage markers. The formation of a mature lymphatic network
involves the function of additional genes, viz., podoplanin, ephrin
B2, neuropilin-2, and FoxC2, and continues throughout the first few
postnatal days. The mature lymphatic network is composed of initial
lymphatic vessels and of collecting vessels covered with smooth
muscle cells (SMC)
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only by lymphatic endothelium, but also by liver sinusoids,
some lung blood vessels, high endothelial venules, and
activated tissue macrophages (Jackson 2003). Recently,
LYVE-1 has been reported to be downregulated upon
incubation of cultured LEC with tumor necrosis factor-
alpha and also in an in vivo inflammation model (Johnson
et al. 2007). However, the potential function of LYVE-1
function remains unclear since LYVE-1 deficient mice do
not exhibit any abnormal phenotype, including lymphatic
development and immune cell trafficking (Gale et al. 2007).
The vascular endothelial growth factor receptor-3
(VEGFR-3, also known as Flt4) is a specific receptor for
the lymphangiogenic factors vascular endothelial growth
factor-C (VEGF-C) and VEGF-D (Tammela et al. 2005a).
Even before the onset of lymphatic vascular differentiation,
VEGFR-3 is highly expressed by blood vascular endothe-
lial cells, but its expression becomes gradually restricted to
lymphatic endothelial cells after mid-gestation (Kaipainen
et al. 1995). In agreement with its early expression in the
blood vasculature, VEGFR-3 deletion in mice causes
cardiovascular failure and embryonic death before the
emergence of the lymphatic vasculature (Dumont et al.
1998). However, VEGFR-3 mutations have been identified
as a cause for the cutaneous lymphedema in Chy mice,
demonstrating the essential role of VEGFR-3 in lymphatic
development and function (Karkkainen et al. 2001). In the
adult, VEGFR-3 expression has also been reported in
proliferating blood vessels during tumor angiogenesis
(Laakkonen et al. 2007; Paavonen et al. 2000), indicating
that VEGFR-3 might also be a mediator of angiogenesis
under these conditions. During embryonic development, its
ligand VEGF-C is produced by vascular smooth muscle
cells and mesenchymal cells in areas adjacent to the sites of
initial sprouting of LECs from veins (Kukk et al. 1996).
The importance of VEGF-C/VEGFR-3 signaling in lym-
phatic development has recently been demonstrated in
embryos homozygous for the VEGF-C deletion. These
mice lack a lymphatic vasculature because of a lack of
sprouting of lymphatically differentiated endothelial cells
(Karkkainen et al. 2004). Whereas VEGF-C −/− mice die at
around E15, VEGF-C +/– mice survive into adulthood but
display severe lymphatic hypoplasia (Karkkainen et al.
2004). Although VEGF-D is able to rescue the sprouting in
VEGF-C −/− embryos, VEGF-D deficient mice do not
exhibit a lymphatic phenotype, indicating that VEGF-D is
dispensable for the development of the lymphatic system
(Baldwin et al. 2005). In culture, both VEGF-C and VEGF-
D promote the proliferation, migration, and survival of
lymphatic endothelial cells via signaling through VEGFR-3
(Makinen et al. 2001).
When LECs further migrate to form the first capillary
networks, they begin to express the mucin-type transmem-
brane glycoprotein podoplanin (Schacht et al. 2003).
Podoplanin is strongly expressed by lymphatic endothelium
but not by blood vascular endothelium in vivo and in vitro
(Breiteneder-Geleff et al. 1999; Hirakawa et al. 2003).
Podoplanin null mice are characterized by lymphedema,
abnormal patterning of the lymphatic vessel network, and
impaired lymphatic transport (Schacht et al. 2003), but the
detailed molecular functions of podoplanin remain un-
known. A number of additional molecules appear to have a
role during lymphatic development. Adrenomedullin,
known as a potent vasodilator, has been recently found to
play a role in lymphatic development based on studies in
several knockout mouse models (Fritz-Six et al. 2008).
Deficiency of adrenomedullin or of its receptors RAMP2 or
calcitonin receptor-like receptor lead to pronounced edema
associated with hypoplastic jugular lymph sacs and death at
mid-gestation. However, whether impaired adrenomedullin
signaling in blood vascular endothelium, associated with
enhanced vascular permeability, contributes to the edema
phenotype remains unclear (Ichikawa-Shindo et al. 2008).
Molecules involved in the maturation of the lymphatic
vascular network
The formation of a mature lymphatic network continues
throughout the first few postnatal days, and mechanisms for
keeping the blood and lymphatic vascular compartments
apart are essential to maintain the proper function of both
networks. Circulating endothelial progenitor cells have
been found to express the tyrosine kinase SYK and its
substrate adaptor molecule SLP-76. Deficiency in SYK or
SLP-76 results in arterio-venous shunting and connections
between blood vessels and blood-filled lymphatic vessels
that show mosaic expression of the lymphatic marker
LYVE-1 (Abtahian et al. 2003; Sebzda et al. 2006). These
findings have been interpreted to demonstrate a role of
circulating progenitor cells for the maintenance of vessel
integrity (Abtahian et al. 2003; Sebzda et al. 2006).
However, a recent report indicates that the lymphatic-
specific glycoprotein podoplanin mediates platelet aggre-
gation via activation of C-type lectin-like receptor 2
(CLEC-2) expressed on platelets, and that this effect
involves the activation of SYK and SLP-76 (Christou et
al. 2008; Suzuki-Inoue et al. 2007). Thus, interactions
between podoplanin and platelet-expressed CLEC-2 might
represent a mechanism for preventing leaks between blood
and lymphatic vessels.
Fasting-induced adipose factor (Fiaf/Angptl4) also
appears to be involved in vascular separation since Fiaf-
deficient mice show dilated and blood-filled intestinal
lymphatics after birth, associated with reduced expression
of the lymphatic marker Prox1 (Backhed et al. 2007). The
underlying mechanisms contributing to this phenotype
remain to be elucidated. Similarly, blood-filled lymphatic
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vessels have been found in embryos deficient in adaptor
proteins of the Spred/Sprouty family, Spred-1 and Spred-2
(Taniguchi et al. 2007). Spreds are known as negative
regulators of growth factor and cytokine-induced ERK
activation and might potentially be involved in the negative
regulation of VEGFR-3 signaling.
Besides vascular separation, additional molecular and
cellular mechanisms are involved in promoting lymphatic
vessel maturation. These include the differentiation of
lymphatic capillaries and the collecting lymphatic network,
the formation of valves, and the coverage of collecting
lymphatic vessels and ducts by smooth muscle cells.
Maintenance of VEGF-C signaling seems to be important
for all of these processes (Karpanen et al. 2006b). An
additional molecule that interacts with VEGF-C and VEGF-
D, viz., neuropilin-2 (Nrp-2), has been shown to be
essential for lymphatic vessel development and maturation,
since Nrp-2 knockout mice fail to develop small-diameter
lymphatic vessels (Yuan et al. 2002). Nrps are non-kinase
type I transmembrane proteins that have an important role
in axon guidance within the nervous system. Whereas Nrp-
1 is mainly expressed by arterial endothelial cells, Nrp-2
expression is restricted to veins and lymphatics (Hong et al.
2002; Karkkainen et al. 2001; Yuan et al. 2002). Nrp-2
serves as a co-receptor for VEGF-C and may enhance
signaling via VEGFR-3 (Karpanen et al. 2006a). Integrins
are also involved in postnatal lymphatic maturation, as
evidenced by the development of chylothorax resulting
from lymphatic fluid accumulation in the pleural cavity in
alpha9 integrin-deficient mice (Huang et al. 2000).
Angiopoietin signaling is necessary for normal blood
vessel development as has been shown in a number of
genetic mouse models (Dumont et al. 1994; Maisonpierre et
al. 1997; Suri et al. 1996). Angiopoietin-1 (Ang1) is an
activating ligand for the endothelial-specific Tie-2 receptor
tyrosine kinase, and paracrine Ang1-mediated activation of
Tie-2 acts as a regulator of vessel maturation and vascular
quiescence. Ang2 deficient mice are characterized by
impaired patterning of the lymphatic vascular network and
recruitment of smooth muscle cells during development.
Interestingly, these phenotypes (but not the blood vascular
abnormalities) can be rescued by Ang1, suggesting that
Ang2 might act as context-dependent agonist of Tie-2
during lymphangiogenesis, whereas it plays an antagonist
role in angiogenesis (Gale et al. 2002). Recent studies
indicate that Ang1 promotes lymphangiogenesis in mice, as
demonstrated by the lymphatic hyperplasia observed after
the adenoviral or transgenic delivery of Ang1 (Tammela et
al. 2005b). The endothelial-restricted expression of Tie-2
has enabled the use of Tie-2 Cre mice for endothelial-
specific gene ablation studies (Forde et al. 2002).
Ephrin/Eph signaling systems are involved in both
angiogenic and lymphangiogenic processes. EphB2 knock-
out mice show defects in LEC sprouting, lymphatic
patterning, and valve-formation and also have the ectopic
coverage of skin lymphatic capillaries by smooth muscle
cells (Makinen et al. 2005). The forkhead transcription
factor FOXC2 is highly expressed in the developing
lymphatic vasculature and in the luminal valves of adult
lymphatic vessels. In Foxc2 deficient mice, the lymphatic
vessels fail to form valves and lymphatic capillaries acquire
ectopic coverage by smooth muscle cells and components
of the basal lamina (Petrova et al. 2004). Overall, studies of
lymphatic development have led to the identification of a
number of novel markers for distinguishing lymphatic and
blood vessels in murine and human tissues (Table 1).
Additional lymphatic growth factors
Hepatocyte growth factor (HGF) has recently been identi-
fied as a potent lymphangiogenic factor (Kajiya et al.
2005). HGF promotes LEC proliferation, migration, and
tube formation via its receptor HGF-R (Fig. 2). The
promigratory effects of HGF are partially mediated by the
alpha9 integrin that is specifically expressed by LECs
(Huang et al. 2000). HGF also promotes lymphangio-
genesis in several organs in vivo, as demonstrated in HGF
transgenic mice (Kajiya et al. 2005). Fibroblast growth
factor-2 (FGF-2) was one of the earliest angiogenic factors
identified and its role in angiogenesis has been well
documented (Auguste et al. 2003). FGF-2 also promotes
lymphangiogenesis by induction of VEGF-C secretion by
blood vascular endothelium and perivascular cells in the
mouse cornea assay (Kubo et al. 2002). Prox1 has been
found to upregulate FGF receptor-3, which binds FGF-2 and
mediates lymphangiogenesis independently of VEGFR-3
activation (Shin et al. 2006). Platelet-derived growth factor-
BB (Cao et al. 2004) and insulin-like growth factors 1 and
2 (Bjorndahl et al. 2005) have been recently identified as
additional factors with lymphangiogenic activity in vitro
and in vivo. In consideration of the number of lymphangio-
genic factors identified and the substantial cross talk with
diverse receptors (Fig. 2), some of these factors may exhibit
complex additive or synergistic effects on lymphatic growth
and function.
Lymphatic involvement in disease
The distinct role of lymphatic vessels in various diseases
has, for a long time, been obscured by the lack of
lymphatic-endothelium-specific markers, growth factors,
and receptors. The recent discovery of lymphatic markers
such as podoplanin, Prox1, and LYVE-1 has made it
possible to distinguish lymphatic vessels from blood
vessels in situ and to isolate LECs for gene expression
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and proteomic profiling studies and for functional in vitro
tests (Hirakawa et al. 2003; Kriehuber et al. 2001; Roesli et
al. 2008). These studies, together with numerous new
genetic mouse models, have provided new insights into the
contribution of lymphatic endothelium to various diseases.
We will focus, in our review, on lymphatic vascular
involvement in lymphedema and in inflammatory diseases,
since the role of lymphatic vessels in cancer metastasis has
Fig. 2 Representation of lym-
phangiogenic growth factors and
their receptors expressed by
lymphatic endothelium. Several
vascular endothelial growth fac-
tors (VEGF-A, VEGF-C, VEGF-
D) promote lymphangiogenesis
by activation of VEGF receptors-
2 and -3 (VEGFR-2, VEGFR-3)
and neuropilin-2 (Nrp2). Addi-
tional lymphatic growth factors
include angiopoietin-1 (ANG-1),
hepatocyte growth factor (HGF),
fibroblast growth factor-2 (FGF-
2), insulin-like growth factors
(IGF-1, IGF-2), platelet-derived
growth factor-BB (PDGF-BB),
and adrenomedullin (AM)
Table 1 Markers for lymphatic (LEC) and blood vascular endothelial (BEC) cells
Marker Molecular function LEC BEC Refrences
Prox1 Transcription factor ++ − Wigle and Oliver 1999
Podoplanin Transmembrane glycoprotein ++ − Schacht et al. 2003
CD31 Adhesion molecule + ++ Albelda et al. 1991
CD34 Adhesion molecule −(+)a ++ Young et al. 1995
CD44 Hyaluronan receptor − + Kriehuber et al. 2001
Lyve1 Hyaluronan receptor ++ − Jackson 2003
Vegfr3 Tyrosine kinase receptor ++ −(+)b Kaipainen et al. 1995
Vegfr1 Tyrosine kinase receptor − + Hirakawa et al. 2003
Vegfr2 Tyrosine kinase receptor + ++ Quinn et al. 1993
Vegf-C Growth factor − + Hirakawa et al. 2003
Nrp-1 Semaphorin and growth factor receptor − + Hong et al. 2002
Nrp-2 Semaphorin and growth factor receptor + −(+)c Yuan et al. 2002
SLC/CCL21 CC-chemokine + − Gunn et al. 1998
CCL20/MIP-3α CC-chemokine + (++)d − (++)d Hirakawa et al. 2003
Endoglin/CD105 Low-affinity receptor for TGF-ß − ++ Hirakawa et al. 2003
Meca-32 Unknown − ++ e Penn et al. 1993
Desmoplakin Anchoring protein of adherens junctions + − Ebata et al. 2001
VE-cadherin Adhesion molecule + ++ Baluk et al. 2007
PAL-E Antibody recognizing Nrp1 − ++f Jaalouk et al. 2007
Interleukin-8 CXC-chemokine − + Petrova et al. 2002
Collagen IV Basement membrane molecule −(+)g ++ Hirakawa et al. 2003
Collagen XVIII Basement membrane molecule −(+)g ++ Hirakawa et al. 2003; Petrova et al. 2002
Integrin alpha9 Adhesion molecule, VEGFR-3 coreceptor + − Huang et al. 2000; Petrova et al. 2002
Macrophage mannose receptor (MRC1) L-selectin receptor + − Irjala et al. 2001
a CD34 expression has also been found on the LECs
b VEGFR-3 expression has been observed in tumor-associated blood vessels
c Neuropilin-2 is also expressed in veins
d Both LECs and BECs express CCL20 after activation
eMeca-32 is an exclusive mouse antigen
f PAL-E recognizes Nrp1. PAL-E labels only human vasculature
g Initial lymphatics lack or have an incomplete basement membrane
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been comprehensively covered in recent reviews (Tobler
and Detmar 2006; Wissmann and Detmar 2006).
Lymphedema
Impaired formation or function of the lymphatic network
results in disfiguring and occasionally life-threatening
swelling of the limbs, called lymphedema (Szuba and
Rockson 1997). Lymphedema can arise as a hereditary
primary disorder or as a secondary disorder. It is accompa-
nied by fibrosis and susceptibility to infections and inflam-
mation (Tabibiazar et al. 2006). Currently, there is no cure
for lymphedema, and available treatments consist predom-
inantly of remedial massage and restrictive bandaging.
Mutations that compromise the development or function
of lymphatic vessels and that lead to lymphedema have
been identified in several human genes. Inactivating mu-
tations in the kinase domain of the VEGFR-3 gene have
been found in congenital lymphedema (Milroy’s disease)
with autosomal dominant inheritance (Brice et al. 2005;
Butler et al. 2007; Karkkainen et al. 2000). These mutations
inhibit phosphorylation of the receptor and prevent its
downstream signaling. VEGFR-3 mutations have been
detected in patients with family history of lymphedema,
although de novo mutations have also been reported
(Ghalamkarpour et al. 2006). Because of a naturally
occurring mutation in VEGFR-3, a similar phenotype is
seen in the Chy mouse (Karkkainen et al. 2001). In
addition, recent studies have identified mutations in the
FOXC2 gene as being responsible for lymphedema-
distichiasis syndrome (Fang et al. 2000; Mangion et al.
1999; Sholto-Douglas-Vernon et al. 2005). The underlying
mechanisms have been elucidated in FOXC2 deficient mice
(Petrova et al. 2004). Mutations of the SOX18 gene, a SRY-
related transcription factor, cause autosomal recessive and
dominant forms of hypotrichosis lymphedema telangiecta-
sia syndrome (Irrthum et al. 2003). The link to the SOX18
gene has been established by the phenotypic homology to
“ragged” mice in which the phenotype is caused by four
different premature truncations in SOX18 (Pennisi et al.
2000). In humans, mutations in the DNA-binding domain
of SOX18 have been found in the recessive form of the
disease, whereas in the dominant form, a heterozygous
nonsense mutation has been found in the transactivation
domain (Irrthum et al. 2003). The expression of SOX18 is
regulated by VEGFR-3 activation and is an early marker of
lymphatic differentiation; however, its detailed function
remains currently unclear (Cermenati et al. 2008).
A point mutation in the nuclear factor kappa B (NFkB)
essential modulator gene NEMO causes a disease with
multiple symptoms, referred to as OL-EDA-ID (osteopet-
rosis, lymphedema, ectodermal dysplasia-anhidrotic, immu-
nodeficiency; Doffinger et al. 2001). This disease indicates
the potential importance of the NFkB pathway in lymphatic
vascular function. Indeed, NFkB has been found to be
constitutively active in lymphatic endothelial cells, al-
though no functional role has as yet been attributed to this
activity (Doffinger et al. 2001).
The major cause of secondary lymphedema in develop-
ing countries is infection with the mosquito-borne parasites
Wuchereria bancrofti and Brugia malayi (Melrose 2002).
This disorder, called lymphatic filariasis and more com-
monly known as elephantiasis, is a painful and profoundly
disfiguring disease characterized by massive damage to the
lymphatic vessels leading to permanent disability. Despite
its major social and economic impact on affected countries,
it is categorized as a neglected tropical disease (Beyrer et al.
2007).
In the industrialized countries, secondary lymphedema is
mainly caused by surgical removal of lymph nodes or
radiation therapy, particularly in patients with breast cancer.
Secondary lymphedema remains a significant clinical
problem with, according to some studies, one out of five
women developing the condition following treatment for
breast cancer (Clark et al. 2005).
The recent identification of growth factors capable of
directly inducing the growth of lymphatic vessels, such as
VEGF-C and VEGF-D, may provide new strategic ap-
proaches for the therapy of lymphedema (Rockson 2005).
Adeno-associated virus-mediated delivery of VEGF-C to
the skin of Chy mice improves the lymphedema phenotype
(Karkkainen et al. 2001). Notably, a mutant form of
VEGFC, viz., VEGF-C156S, that selectively binds
VEGFR-3 but not VEGFR-2 successfully induces the
formation of cutaneus lymphatic networks without causing
blood vessel leakage, an overt effect observed with wild-
type VEGF-C therapy (Saaristo et al. 2002). Therapy with
VEGF-C protein has also been successfully applied in a
surgical lymphedema model in the rabbit ear (Szuba et al.
2002). Importantly, treatment of lymph node-excised mice
with adenovirally delivered human VEGF-C or VEGF-D
results in a considerable improvement of the lymphatic
draining function, associated with regeneration of mature
lymphatic vessels. VEGF-C therapy also greatly improves
the outcome of lymph node transplantation, indicating a
potential treatment strategy for secondary lymphedema
(Tammela et al. 2007).
Inflammation-associated lymphangiogenesis
Inflammation is the normal response of the body to injury
or infection but may also develop and persist in the context of
autoimmune diseases and during tumor growth. Inflammation
has also long been known to induce pronounced changes of
the blood vasculature thereby significantly contributing to the
clinical symptoms of inflammation: redness, warmth, and
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swelling (Pober and Sessa 2007). In addition to angiogenesis,
recent studies have detected pronounced lymphangiogenesis
in mouse models of chronic airway inflammation, psoriasis,
and rheumatoid arthritis (Baluk et al. 2005; Kunstfeld et al.
2004; Paavonen et al. 2002; Zhang et al. 2007). In particular,
pronounced lymphatic hyperplasia occurs in human psoriatic
skin lesions and also in a VEGF-A transgenic mouse
psoriasis model (Kunstfeld et al. 2004). In inflamed tissues,
the lymphangiogenic factors VEGF-C and VEGF-A are
secreted by immune cells such as macrophages or by
resident tissue cells such as fibroblasts and keratinocytes
(Ristimaki et al. 1998). Unpublished observations from our
laboratory suggest that lymphangiogenesis is also associ-
ated with inflammatory bowel disease in a mouse model
of interleukin-10 deficiency (Fig. 3). These findings
indicate a potential involvement of the lymphatic vascular
system in the pathogenesis of human inflammatory bowel
syndromes (ulcerative colitis and Crohn’s disease) in which
lymphatic hyperplasia has scarcely been studied (Pedica et
al. 2008).
Recently, we have found that acute ultraviolet B (UVB)
irradiation of murine skin results in leaky, functionally
impaired lymphatics, and that blockade of VEGFR-3
prolongs UVB-irradiation-induced inflammation (Kajiya et
al. 2007). Importantly, studies in mice indicate that UVB-
mediated upregulation of VEGF-A induces lymphatic
hyperpermeability that can be blocked by systemic appli-
cation of an anti-VEGF-A antibody (Kajiya et al. 2006).
Furthermore, the nitric oxide/soluble guanylate cyclase
alpha1beta1/cGMP pathway has been found to modulate
lymphatic vessel function in UVB-irradiation-caused in-
flammation, indicating that blockade of soluble guanylate
cyclase might represent a novel therapeutic strategy for
inhibiting lymphangiogenesis and inflammation (Kajiya et
al. 2008).
Lymphatic vessels also play a key role in the migration
of dendritic cells to draining lymph nodes where they
initiate the adaptive immune response (Halin and Detmar
2006). Mature inflammatory-signal-activated dendritic cells
upregulate the expression of chemokine receptor CCR7.
Lymphatic endothelium actively secretes the respective
ligand, CCL21, causing dendritic cell chemotaxis toward
lymphatic vessels (Bromley et al. 2005; Debes et al. 2005).
CCR7 might also mediate the exit of CD4+ memory T cells
from tissues to lymphatic vessels (Yuan et al. 2002).
Furthermore, inflammatory stimuli have been reported to
increase the lymph flow, which promotes dendritic cell
migration to lymph nodes (Gunn et al. 1998). There is
increasing evidence that inflammation-induced expression
of adhesion molecules on lymphatic endothelium might
facilitate the exit of dendritic cells and lymphocytes into
lymphatic vessels. Incubation of LECs with tumor
necrosis factor-alpha upregulates the expression of inter-
cellular adhesion molecule-1 (ICAM-1), vascular adhesion
molecule-1 (VCAM-1), and E-selectin, and systemic
blockade of ICAM-1 and VCAM-1 has been reported to
inhibit inflammation-induced lymphatic transmigration in
vivo (Johnson et al. 2006). Sphingosine-1-phosphate (S1P)
and its receptor S1P1/EDG1 have been implicated in the
process of lymphocyte egress from the thymus and lymph
nodes (Halin et al. 2005; Matloubian et al. 2004). Recent
data indicate that stimulation of S1P1 on T lymphocytes by
the S1P1 agonist FTY720 inhibits their migration across the
endothelium of afferent lymphatic vessels, leading to reten-
tion of T lymphocytes in peripheral tissues (Ledgerwood et
al. 2008).
Interestingly, lymphangiogenesis is also observed in the
lymph nodes draining the inflamed tissue, indicating a
remote control by drainage of lymphangiogenic factors
from peripheral tissues, although secretion of lymphangio-
genic factors by cells residing within lymph nodes might
contribute to this effect (Angeli et al. 2006; Halin et al.
2007).
Overall, the biological role of lymphangiogenesis in the
pathogenesis of chronic inflammation needs further clarifi-
cation. On one hand, activation of lymphatic vessels might
Fig. 3 Lymphangiogenesis in colon inflammation. Whereas wild-type
mice show normal lymphatic vasculature in the submucosal area of the
colon wall (a), C3H/HeJBir.Il10−/− mice display dramatically enlarged
and tortuous lymphatic vessels accompanying the colon inflammation
(b). Stained for the lymphatic vessel marker LYVE-1 (red); counter-
stained with hematoxylin. Bars 100 μm
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promote immune cell trafficking to the draining lymph
nodes, thereby supporting the establishment of an inflam-
matory loop. Indeed, lymphangiogenesis has been proposed
to contribute to renal transplant rejection by promoting the
export of CCR7-positive inflammatory cells guided by
LEC-derived CCL21 (Kerjaschki et al. 2004). Moreover,
blockade of VEGFR-3 in the initial stage of inflammation
in mouse corneas impairs dendritic cell trafficking to
draining lymph nodes, the induction of delayed-type
hypersensitivity, and the rejection of corneal transplants
(Chen et al. 2004). On the other hand, lymphangiogenesis
might be beneficial for the resolution of chronic inflamma-
tion since lymphatic vessels drain, and thereby remove,
accumulated fluid, immune cells, and inflammatory cyto-
kines from the sites of inflammation. Indeed, inhibition of
VEGFR-3 signaling has been found to impair the lymphatic
vascular network and to promote mucosal edema in a
mouse model of chronic airway inflammation (Baluk et al.
2005). Further experimental studies and observations in
human inflammatory conditions indicate that impaired
lymphatic drainage leads to the exacerbation of disease
(Kajiya et al. 2007; Middel et al. 2006; Ryan 1980). VEGF-
A and VEGF-C appear to exert opposing effects in chronic
inflammation (Halin et al. 2007; Kajiya et al. 2006, 2007).
Whereas VEGF-A might promote inflammation by inducing
more leaky and non-functional lymphatic vessels, VEGF-C
seems to promote lymphatic flow and the resolution of
inflammation. However, more experimental evidence is
required to support this concept further. Taken together, the
emerging role of lymphatic endothelium in the context of
inflammation indicates that anti-inflammatory therapeutics
targeting the lymphatic vasculature might represent a new
strategy to improve the lives of patients with inflammatory
conditions.
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